期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 25, 期 3, 页码 601-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2016.02.011
关键词
Molecular; Targeted therapy; Immunotherapy; Non-small cell lung cancer
Targeted therapy and immunotherapy have changed the treatment paradigm of non-small cell lung cancer (NSCLC). Distinct molecular sub-types of NSCLC have been described over the past 20 years, enabling the emergence of treatments specific to that subtype. Agents targeting the driver mutations in NSCLC have revolutionized the approach to patients with metastatic disease, because oncologists now select a treatment based on the profile of that particular tumor. More recently, an understanding of immune checkpoints has led to the development of checkpoint inhibitors that enable the host immune system to better recognize tumor cells as foreign and to destroy them.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据